Prostate specific antigen doubling time (PSA-DT) and velocity (PSA-V) provide independent prognostic information in androgen independent prostate cancer (AIPC) patients receiving chemotherapy
Daskivich T, Regan M, Kantoff P, Oh W. Prostate specific antigen doubling time (PSA-DT) and velocity (PSA-V) provide independent prognostic information in androgen independent prostate cancer (AIPC) patients receiving chemotherapy. Journal Of Clinical Oncology 2006, 24: 4616-4616. DOI: 10.1200/jco.2006.24.18_suppl.4616.Peer-Reviewed Original ResearchAndrogen-independent prostate cancerAndrogen deprivation therapyAssociated with decreased OSPSA-DTOverall survivalPSA nadirTaxane chemotherapyLow HbFailure of androgen deprivation therapyProstate specific antigen doubling timePredictors of decreased OSPSA nadir >Short PSA DTIndependent prostate cancerType of chemotherapyCox proportional hazards regressionHigh M stagePSA-VProportional hazards regressionLog-PSADeprivation therapyPSA valuesIntermediate prognosisPrognostic factorsPrognostic significance
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply